在自身减肥药研发遭遇挫折后，辉瑞正通过一笔重大收购重新布局，以期在这个规模有望突破千亿美元的赛道中占据一席 之地。 据媒体22日报道，辉瑞已接近达成一项交易，计划以高达73亿美元的总价收购减肥药开发商Metsera。报道称，辉瑞将以每 股47.50美元的现金收购这家总部位于纽约的公司，并根据特定业绩里程碑的达成情况，额外支付最高每股22.50美元。 这一收购价较Metsera周五33.32美元的收盘价溢价约42.5%。周一Metsera股价大涨，盘中一度涨超62%，最终仍收涨逾 60%，市值达到约56亿美元。 Metsera成立于2022年，由风险投资公司ARCH Venture和投资公司Population Health Partners创立。该公司正基于GLP-1机制 和其他生物靶点开发注射和口服肥胖治疗药物。公司的主要候选药物MET-097i是一种注射剂，在今年早些时候的中期试验 中显示患者平均减重11.3%。 市场竞争日趋激烈 收购标的Metsera：备受瞩目的行业新秀 根据交易条款，辉瑞提出的每股47.50美元现金报价，相较于Metsera上周五的收盘价存在显著溢价。按该收盘价计算， Metsera ...

公司战略与收购 - 辉瑞公司正在通过收购Metsera及其四种药物组合来扩大其减肥药物产品线 [1] - 此次收购旨在满足市场对减肥药物日益增长的需求 [1] 药物组合与市场机会 - Metsera拥有四种针对减肥治疗的药物组合 [1] - 辉瑞公司认为更多人群将寻求减肥解决方案 因此加强在该领域的布局 [1]

U.S. equity markets continued their robust performance on Monday, September 22, 2025, with major indexes extending their record-setting rally. Despite an early morning dip attributed to profit-taking and concerns over a potential government shutdown, afternoon trading saw a strong recovery, buoyed by optimistic investor sentiment following last week's Federal Reserve interest rate cut and significant corporate news in the technology and pharmaceutical sectors.Current Market Indexes and Afternoon ActivityThe ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Key Points Pfizer will buy Metsera for at least $47.50 per share. Pfizer could end up paying closer to $70 per share. Pfizer wants to sell GLP-1 weight loss drugs, and Metsera has four such candidates. 10 stocks we like better than Pfizer › Pfizer (NYSE: PFE), the one-time COVID vaccine hero turned Ozempic craze zero, is marching higher Monday after announcing it will try to recover from its danuglipron setback by buying another drug company with weight loss dreams. As of 12:25 p.m. ET, Pfizer st ...

Pfizer Inc. will pay $4.9 billion for the obesity startup Metsera Inc. in a bid to catch up to rival drugmakers after failing to compete with its own weight-loss medications. The US drugmaker agreed to buy Metsera for $47.50 in cash per share, and further payments of up to $22.50 per share if three specific and regulatory milestones are met, it said Monday, with a total potential value of $7.3 billion. The deal represents a 43% premium to Metsera's closing share price on Friday. Bloomberg's Sam Fazeli repo ...

Pfizer has acquired Metsera for $4.9bn, as the drugmaker targets longer-lasting glucagon-like peptide-1 receptor agonists (GLP-1RAs) to cement market share in the burgeoning weight loss treatment sector. Pfizer has agreed to buy all of Metsera’s shares for a price of $47.50 each, representing a 43% premium to Metsera’s closing share price of $33.32 on 19 September. The deal, forecast to close in Q4 2025, also includes potential additional payments of up to $22.50 per share in cash tied to three specific c ...

SAN DIEGO, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP, has launched an investigation into whether the board members of Metsera, Inc. (NASDAQ: MTSR) breached their fiduciary duties in connection with the proposed sale of the Company to Pfizer, Inc. (NYSE: PFE). Background: On September 21, 2025, Metsera and Pfizer entered into a definitive merger agreement. Under the terms of the agreement, holders of Metsera’s common stock will receive $47.50 per share in cash. In a ...

I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up to Growth Stock Forum.Pfizer Inc. (NYSE: PFE ) announced today that it will acquire Metsera, Inc. (NASDAQ: MTSR ...